Abstract
This article discusses the results of an analysis of data from a subgroup of patients in the TRITON-TIMI 38 study [NCT00097591; Wiviott et al. N Engl J Med 2007] who were receiving proton pump inhibitor therapy in addition to a thienopyridine (prasugrel or clopidogrel). The results showed no association between PPI use and an increased risk of cardiovascular events [O'Donoghue M et al. Lancet 2009].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
